📊 BLFS Key Takeaways
Is Biolife Solutions Inc. (BLFS) a Good Investment?
Strong 28.9% revenue growth and 77.2% net income improvement are undermined by negative operating cash flow (-$491K) and near-zero operating margin (0.1%), indicating earnings quality concerns and unsustainable profitability. Despite fortress-like balance sheet strength, the company generates minimal returns on its $400.9M asset base, signaling severe operational inefficiency.
BioLife Solutions shows strong fundamental momentum with 28.9% revenue growth, high 64.6% gross margins, and positive free cash flow, indicating that growth is translating into real cash generation. The balance sheet is exceptionally strong with high liquidity, minimal leverage, and substantial equity support, which reduces financial risk while management works toward sustained operating profitability. The main constraint is that the business is still posting operating losses, so the case depends on continued margin improvement and disciplined cost control.
Biolife Solutions Inc. Key Strengths (BLFS)
- Exceptional revenue growth of 28.9% YoY with net income surging 77.2%
- Fortress balance sheet with 7.30x current ratio, minimal leverage (0.01x D/E), and $22.8M cash reserves
- Robust gross margin of 63.6% demonstrates strong unit economics and product pricing power
- Strong top-line growth supported by positive operating and free cash flow
- High gross margin profile suggests attractive unit economics and pricing power
- Very strong balance sheet with high liquidity and negligible debt
BLFS Stock Risks: Biolife Solutions Inc. Investment Risks
- Negative operating cash flow of -$491K despite positive net income signals earnings quality deterioration and working capital strain
- Operating margin of 0.1% reveals severe SG&A/operating expense bloat despite strong gross margins, indicating core business struggles
- Abysmal ROE (0.3%) and ROA (0.3%) show extreme capital inefficiency; company not generating adequate returns from $372.2M equity base
- Operating margin remains meaningfully negative, showing the business has not reached durable earnings leverage
- Net income is still negative, so profitability improvement is not yet fully proven
- Cash generation could weaken if revenue growth slows or operating expenses remain elevated
Key Metrics to Watch
- Operating cash flow trajectory and sustainability of cash generation
- Operating margin expansion or contraction relative to revenue growth
- Return on equity and return on assets improvement to validate capital deployment efficiency
- Operating margin trend
- Free cash flow consistency
Biolife Solutions Inc. (BLFS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.30x current ratio provides a solid financial cushion.
BLFS Profit Margin, ROE & Profitability Analysis
BLFS vs Healthcare Sector: How Biolife Solutions Inc. Compares
How Biolife Solutions Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biolife Solutions Inc. Stock Overvalued? BLFS Valuation Analysis 2026
Based on fundamental analysis, Biolife Solutions Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biolife Solutions Inc. Balance Sheet: BLFS Debt, Cash & Liquidity
BLFS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Biolife Solutions Inc.'s revenue has declined by 19% over the 5-year period, indicating business contraction. The most recent EPS of $-1.55 indicates the company is currently unprofitable.
BLFS Revenue Growth, EPS Growth & YoY Performance
BLFS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $22.1M | -$448.0K | $0.00 |
| Q3 2025 | $21.4M | $621.0K | $0.01 |
| Q2 2025 | $19.7M | -$15.8M | $-0.33 |
| Q1 2025 | $18.4M | -$448.0K | $-0.01 |
| Q3 2024 | $23.6M | -$1.7M | $-0.04 |
| Q2 2024 | $28.3M | -$10.2M | $-0.23 |
| Q1 2024 | $31.7M | -$10.2M | $-0.22 |
| Q3 2023 | $33.3M | -$10.3M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Biolife Solutions Inc. Dividends, Buybacks & Capital Allocation
BLFS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biolife Solutions Inc. (CIK: 0000834365)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BLFS
What is the AI rating for BLFS?
Biolife Solutions Inc. (BLFS) has a Combined AI Grade of B from Claude (C) and ChatGPT (A) with 68% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BLFS's key strengths?
Claude: Exceptional revenue growth of 28.9% YoY with net income surging 77.2%. Fortress balance sheet with 7.30x current ratio, minimal leverage (0.01x D/E), and $22.8M cash reserves. ChatGPT: Strong top-line growth supported by positive operating and free cash flow. High gross margin profile suggests attractive unit economics and pricing power.
What are the risks of investing in BLFS?
Claude: Negative operating cash flow of -$491K despite positive net income signals earnings quality deterioration and working capital strain. Operating margin of 0.1% reveals severe SG&A/operating expense bloat despite strong gross margins, indicating core business struggles. ChatGPT: Operating margin remains meaningfully negative, showing the business has not reached durable earnings leverage. Net income is still negative, so profitability improvement is not yet fully proven.
What is BLFS's revenue and growth?
Biolife Solutions Inc. reported revenue of $27.5M.
Does BLFS pay dividends?
Biolife Solutions Inc. does not currently pay dividends.
Where can I find BLFS SEC filings?
Official SEC filings for Biolife Solutions Inc. (CIK: 0000834365) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BLFS's EPS?
Biolife Solutions Inc. has a diluted EPS of $0.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BLFS's fundamental grade?
Based on our AI fundamental analysis in June 2026, Biolife Solutions Inc. has a B grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BLFS stock overvalued or undervalued?
Valuation metrics for BLFS: ROE of 0.3% (sector avg: 15%), net margin of 4.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BLFS's AI grade for 2026?
Our dual AI analysis gives Biolife Solutions Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BLFS's free cash flow?
Biolife Solutions Inc.'s operating cash flow is $-491.0K, with capital expenditures of $167.0K. FCF margin is -2.4%.
How does BLFS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.3% (avg: 12%), ROE 0.3% (avg: 15%), current ratio 7.30 (avg: 2).